BIO-TISSUE HAS BEEN A PIONEER IN scientific research and innovation in regenerative medicine with more than 30 years of NIH-supported research, 300 peer-reviewed publications, and 300,000 allograft transplantations. These milestones reflect our dedication to the mission of developing novel solutions to restore and maintain ocular surface health. In fact, cryopreserved amniotic membrane has been used clinically for 20 years and is now a standard of care for many ocular conditions. Yet, this technology offers the potential to continue to improve clinical outcomes in this field, particularly if utilized earlier in the continuum of care. Early effective intervention promises not only to improve outcomes, but also offers health economics advantages.

At the recent American Academy of Ophthalmology in New Orleans, a group of leading ophthalmologists presented their groundbreaking clinical experience with the use of cryopreserved amniotic membrane. This clinical supplement provides a summary of their findings and highlights key considerations for the implementation of cryopreserved amniotic membrane in clinical practice to optimize clinical outcomes in the treatment of dry eye disease and cataract surgery.

We thank you for taking the time to continue to learn about our proprietary tissue technology and how to implement its use in your surgical and clinical practice. At the same time, we remain steadfast in our commitment to innovate technologies that promise better outcomes for your patients and to deliver the evidence-based support that you demand as a clinician.

Thank you for your support.

Amy Tseng
President and CEO, Bio-Tissue